Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.

Rakhsha SS, Shahinfar H, Ebrahimi-Mousavi S, Kosari A, Aali Y, Mirzababaei A, Hosseini SA, Jadidi P, Shafiee G, MansourZadeh MJ, Heshmat R, Mastouri D

Diabetes, obesity & metabolism16 Jun 2026Cited by 1 (Europe PMC)

PMID42304171PMCIDPMC13449080DOI10.1111/dom.70957PepBankPUB-42304171

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized-trial participants, tirzepatide reduced fat mass versus placebo (MD -10.70 kg, 95% CI -13.42 to -7.99).
In plain wordsIn a network analysis of randomized-trial participants, tirzepatide reduced fat mass more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseFat mass
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference
−10.7 kg
versus placebo; 95% CI -13.42 to -7.99
Source sentences
Summary
For FM among Glucagon-like peptide-1 (GLP-1) and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, tirzepatide showed the greatest reduction compared with placebo (MD -10.70 kg; 95% CI: -13.42 to -7.99), followed by liraglutide plus exercise.
3 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials.
Summary · context
Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in fat mass (FM) and lean body mass (LBM).
Summary · context
Forty-one trials involving 2906 participants were included.
Report a problemFND-4230417101
02HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized-trial participants, semaglutide produced moderate fat-mass reductions.
In plain wordsIn a network analysis of randomized-trial participants, semaglutide produced moderate fat-mass reductions.
Peptide
Semaglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide and liraglutide produced moderate reductions.
4 context sentences(design, population, supporting numbers)
Summary · context
For FM among Glucagon-like peptide-1 (GLP-1) and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, tirzepatide showed the greatest reduction compared with placebo (MD -10.70 kg; 95% CI: -13.42 to -7.99), followed by liraglutide plus exercise.
Summary · context
PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials.
Summary · context
Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in fat mass (FM) and lean body mass (LBM).
Summary · context
Forty-one trials involving 2906 participants were included.
Report a problemFND-4230417103
03HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized-trial participants, liraglutide produced moderate fat-mass reductions.
In plain wordsIn a network analysis of randomized-trial participants, liraglutide produced moderate fat-mass reductions.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide and liraglutide produced moderate reductions.
4 context sentences(design, population, supporting numbers)
Summary · context
For FM among Glucagon-like peptide-1 (GLP-1) and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, tirzepatide showed the greatest reduction compared with placebo (MD -10.70 kg; 95% CI: -13.42 to -7.99), followed by liraglutide plus exercise.
Summary · context
PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials.
Summary · context
Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in fat mass (FM) and lean body mass (LBM).
Summary · context
Forty-one trials involving 2906 participants were included.
Report a problemFND-4230417104
04HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized-trial participants, tirzepatide was associated with significantly reduced lean body mass (MD -4.40 kg, 95% CI -7.58 to -1.22); the comparator was unstated.
In plain wordsIn a network analysis of randomized-trial participants, tirzepatide was linked to lower lean body mass; the comparator was unstated.
Peptide
Tirzepatide
Outcome
DecreaseLean body mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated
Measurements
Mean difference
−4.4 kg
95% CI -7.58 to -1.22
Source sentences
Summary
For LBM, tirzepatide (MD -4.40 kg; 95% CI: -7.58 to -1.22) and liraglutide (MD -1.54 kg; 95% CI: -2.55 to -0.52) were associated with significant reductions.
3 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials.
Summary · context
Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in fat mass (FM) and lean body mass (LBM).
Summary · context
Forty-one trials involving 2906 participants were included.
Report a problemFND-4230417105
05HumanSystematic reviewEfficacy outcome
In a network meta-analysis of randomized-trial participants, liraglutide was associated with significantly reduced lean body mass (MD -1.54 kg, 95% CI -2.55 to -0.52); the comparator was unstated.
In plain wordsIn a network analysis of randomized-trial participants, liraglutide was linked to lower lean body mass; the comparator was unstated.
Peptide
Liraglutide
Outcome
DecreaseLean body mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated
Measurements
Mean difference
−1.54 kg
95% CI -2.55 to -0.52
Source sentences
Summary
For LBM, tirzepatide (MD -4.40 kg; 95% CI: -7.58 to -1.22) and liraglutide (MD -1.54 kg; 95% CI: -2.55 to -0.52) were associated with significant reductions.
3 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials.
Summary · context
Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in fat mass (FM) and lean body mass (LBM).
Summary · context
Forty-one trials involving 2906 participants were included.
Report a problemFND-4230417106

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a network meta-analysis of randomized-trial participants, liraglutide plus exercise ranked after tirzepatide for fat-mass reduction.
In plain wordsIn a network analysis of randomized-trial participants, liraglutide plus exercise ranked after tirzepatide for fat-mass reduction.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
For FM among Glucagon-like peptide-1 (GLP-1) and dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, tirzepatide showed the greatest reduction compared with placebo (MD -10.70 kg; 95% CI: -13.42 to -7.99), followed by liraglutide plus exercise.
3 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Web of Science and Scopus were searched from inception to March 2025 for randomized controlled trials.
Summary · context
Network meta-analyses used a frequentist random-effects framework to estimate mean differences (MDs) and 95% confidence intervals (CIs) for changes in fat mass (FM) and lean body mass (LBM).
Summary · context
Forty-one trials involving 2906 participants were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4230417102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.